ALEMBIC PHARMA | STERLING BIOTECH | ALEMBIC PHARMA/ STERLING BIOTECH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 17.0 | -0.4 | - | View Chart |
P/BV | x | 6.8 | 0.0 | 47,518.6% | View Chart |
Dividend Yield | % | 0.6 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-19 |
STERLING BIOTECH Dec-13 |
ALEMBIC PHARMA/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 664 | 11 | 6,323.8% | |
Low | Rs | 412 | 3 | 12,129.4% | |
Sales per share (Unadj.) | Rs | 208.7 | 26.8 | 778.6% | |
Earnings per share (Unadj.) | Rs | 31.0 | -15.0 | -207.2% | |
Cash flow per share (Unadj.) | Rs | 37.1 | -5.5 | -679.3% | |
Dividends per share (Unadj.) | Rs | 5.50 | 0 | - | |
Dividend yield (eoy) | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 144.2 | 54.9 | 262.8% | |
Shares outstanding (eoy) | m | 188.52 | 267.87 | 70.4% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.6 | 0.3 | 994.6% | |
Avg P/E ratio | x | 17.4 | -0.5 | -3,736.5% | |
P/CF ratio (eoy) | x | 14.5 | -1.3 | -1,139.9% | |
Price / Book Value ratio | x | 3.7 | 0.1 | 2,946.9% | |
Dividend payout | % | 17.7 | 0 | - | |
Avg Mkt Cap | Rs m | 101,461 | 1,862 | 5,449.9% | |
No. of employees | `000 | NA | 1.4 | 0.0% | |
Total wages/salary | Rs m | 7,467 | 547 | 1,365.6% | |
Avg. sales/employee | Rs Th | NM | 5,303.3 | - | |
Avg. wages/employee | Rs Th | NM | 403.8 | - | |
Avg. net profit/employee | Rs Th | NM | -2,959.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,347 | 7,181 | 548.0% | |
Other income | Rs m | 94 | 43 | 220.2% | |
Total revenues | Rs m | 39,441 | 7,223 | 546.0% | |
Gross profit | Rs m | 8,736 | 947 | 922.6% | |
Depreciation | Rs m | 1,152 | 2,543 | 45.3% | |
Interest | Rs m | 184 | 4,377 | 4.2% | |
Profit before tax | Rs m | 7,493 | -5,931 | -126.3% | |
Minority Interest | Rs m | 11 | 0 | - | |
Prior Period Items | Rs m | -93 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,568 | -1,924 | -81.5% | |
Profit after tax | Rs m | 5,844 | -4,007 | -145.9% | |
Gross profit margin | % | 22.2 | 13.2 | 168.4% | |
Effective tax rate | % | 20.9 | 32.4 | 64.5% | |
Net profit margin | % | 14.9 | -55.8 | -26.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,577 | 14,335 | 136.6% | |
Current liabilities | Rs m | 14,896 | 49,809 | 29.9% | |
Net working cap to sales | % | 11.9 | -494.0 | -2.4% | |
Current ratio | x | 1.3 | 0.3 | 456.7% | |
Inventory Days | Days | 90 | 403 | 22.2% | |
Debtors Days | Days | 45 | 171 | 26.6% | |
Net fixed assets | Rs m | 27,097 | 55,432 | 48.9% | |
Share capital | Rs m | 377 | 268 | 140.7% | |
"Free" reserves | Rs m | 26,811 | 13,935 | 192.4% | |
Net worth | Rs m | 27,188 | 14,701 | 184.9% | |
Long term debt | Rs m | 4,993 | 9,478 | 52.7% | |
Total assets | Rs m | 47,778 | 73,988 | 64.6% | |
Interest coverage | x | 41.7 | -0.4 | -11,748.3% | |
Debt to equity ratio | x | 0.2 | 0.6 | 28.5% | |
Sales to assets ratio | x | 0.8 | 0.1 | 848.6% | |
Return on assets | % | 12.6 | 0.5 | 2,518.8% | |
Return on equity | % | 21.5 | -27.3 | -78.9% | |
Return on capital | % | 23.6 | -6.4 | -367.3% | |
Exports to sales | % | 0 | 25.9 | 0.0% | |
Imports to sales | % | 0 | 0.2 | 0.0% | |
Exports (fob) | Rs m | NA | 1,860 | 0.0% | |
Imports (cif) | Rs m | NA | 12 | 0.0% | |
Fx inflow | Rs m | 19,453 | 1,860 | 1,046.0% | |
Fx outflow | Rs m | 6,065 | 25 | 24,366.4% | |
Net fx | Rs m | 13,388 | 1,835 | 729.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,120 | 1,719 | 472.4% | |
From Investments | Rs m | -7,556 | -3,148 | 240.0% | |
From Financial Activity | Rs m | 590 | 1,426 | 41.4% | |
Net Cashflow | Rs m | 1,153 | -3 | -33,920.6% |
Indian Promoters | % | 74.1 | 33.9 | 218.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.9 | 0.0 | - | |
FIIs | % | 9.1 | 9.9 | 91.9% | |
ADR/GDR | % | 0.0 | 16.9 | - | |
Free float | % | 13.9 | 39.3 | 35.4% | |
Shareholders | 49,328 | 21,482 | 229.6% | ||
Pledged promoter(s) holding | % | 0.0 | 55.9 | - |
Compare ALEMBIC PHARMA With: GSK PHARMA ASTRAZENECA PHARMA BIOCON IPCA LABS JUBILANT LIFE SCIENCES
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 140 points, up 0.3% at 49,538 levels.
ALEMBIC PHARMA share price is trading down by 5% and its current market price is Rs 1,041. The BSE HEALTHCARE is up by 0.1%. The top gainers in the BSE HEALTHCARE Index are SHILPA MEDICARE (up 2.9%) and LAURUS LABS (up 2.4%). The top losers is ALEMBIC PHARMA (down 5.1%).
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More